EGFR and non-small cell lung carcinoma: Our results were consistent with previous studies that patients with TP53 concomitant mutations had a lower ORR and shorter PFS of EGFR-TKI treatment compared to patients without TP53 alterations in advanced NSCLC, and none of these studies reached statistical significance (34, 35, 67–69).